Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Leverages Higher Return On OTC R&D Investment To Drive Growth – Witty

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline will be investing more R&D dollars in its consumer health care business, where spending on innovation pays off more quickly and more consistently than in the prescription sector, CEO Andrew Witty says
Advertisement

Related Content

NanoBio's OTC Route For Cold Sore Med Pays Off With GSK Deal
NanoBio's OTC Route For Cold Sore Med Pays Off With GSK Deal
NanoBio's OTC Route For Cold Sore Med Pays Off With GSK Deal
NanoBio's Decision To Go OTC With Its Cold Sore Med Pays Off With GSK Deal
GSK Plans To Wield Aggressive Bolt-On Acquisition Strategy
With Biotene Acquisition, Glaxo Tries Again In Dry Mouth Category
Diversification Versus Focus Dilemma Spotlights OTC Business Value
Alli Sales Slender On Lower Retailer Demand, Flatten GSK Consumer Sales
Alli Sales Slender On Lower Retailer Demand, Flatten GSK Consumer Sales
GSK Looks To Expand OTC Reach With CNS Brands

Topics

Advertisement
UsernamePublicRestriction

Register

PS101977

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel